Back to the full story12 sources · Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.◆ Analytics
Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.
Deterministic text analytics computed across all 12 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
vaccinecancermelanomamodernamerckmrnashowstrialrecurrencepreventing
Top phrases
cancer vaccinemoderna and merckshows promisevaccine showslate stageexperimental vaccinecancer vaccine showsmrna cancer vaccinemerck and modernamrna cancer
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Merck · 11 sources
- Moderna · 11 sources
- Keytruda · 7 sources
- Merck’s · 4 sources
- Intismeran · 3 sources
- Pharmaceutical · 3 sources
- Phase · 3 sources
- Aria Bendix · 2 sources
- Bancel · 2 sources
- Cancer · 2 sources
- CEO · 2 sources
- Moderna’s · 2 sources
Unique to one source
- Moderna's · Al Jazeera
- Personalized · ABC7 Los Angeles
- Merck's Keytruda · Fortune
- Covid · Fortune
- Fortune · Fortune
- The Phase · Ars Technica
- Merck's · Ars Technica
- Both · Ars Technica
- NBC News · NBC News
- Promising Results · Time
- Cancer Vaccine · Time
- Combining · Time
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
- "“For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational." · 2 sources
Appears once
- "Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials." · Al Jazeera
- "The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone." · CNBC
- "The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda." · MarketWatch
- "Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients." · The New York Times
- "Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma." · ABC7 Los Angeles
- "The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients." · Fortune
- "Moderna and Merck said Wednesday their personalized mRNA cancer vaccine met its main goals in a Phase 3 trial targeting melanoma, marking the first time a therapy of its kind has succeeded at that stage of testing." · Fortune
- "Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer." · CBS News — Top